On Monday, UBS has revised its price target for CareMax Inc. (NASDAQ: NASDAQ:CMAX), a healthcare provider, moving it down to $6.40 from the previous $7.00. Despite this change, the firm has decided to maintain a Neutral rating on the company's shares.
The adjustment comes as UBS updates its model to reflect ongoing market challenges. The new price target is derived from applying a consistent 9.0x multiple to the adjusted EBITDA less-SBC (stock-based compensation) forecast for the year 2027, with this figure then discounted to the target date at a 15.0x cost of equity.
In conjunction with the price target revision, UBS has also modified its adjusted EBITDA projections for CareMax. The firm's estimate for the year 2025 has been reduced to $23.6 million, down from the previous forecast of $26.7 million. Similarly, the 2027 adjusted EBITDA estimate has been lowered to $88.4 million from the earlier prediction of $95.7 million.
These updates by UBS reflect a cautious approach towards CareMax's financial outlook over the next few years, taking into account the less favorable conditions that are currently affecting the healthcare sector. The firm's unchanged multiple suggests a steady view of the company's value relative to its earnings before interest, taxes, depreciation, and amortization, after adjusting for stock-based compensation.
InvestingPro Insights
As UBS revises its stance on CareMax Inc. (NASDAQ: CMAX), it's important for investors to consider the financial health and market performance of the company. InvestingPro data indicates a market capitalization of $18.33 million USD, underscoring the company's relatively small size in the healthcare sector. The data also shows a significant revenue growth of 19.01% over the last twelve months as of Q4 2023, which may reflect the company's ability to expand its business despite market challenges.
However, the InvestingPro Tips highlight several concerns. CareMax operates with a significant debt burden and is quickly burning through cash. Moreover, the company's stock has been characterized by high price volatility, and analysts are not expecting profitability this year. These factors, combined with a gross profit margin of just 1.85% over the last twelve months as of Q4 2023, suggest that investors should exercise caution.
For those considering a deeper analysis, the InvestingPro platform offers additional insights, including a total of 13 InvestingPro Tips for CareMax, which can provide a more comprehensive understanding of the company's financial and operational status. To access these tips and more, investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
With the next earnings date approaching on May 8, 2024, and considering the recent performance where the stock price has fallen significantly over the last year, it's clear that CareMax faces a critical period ahead. The InvestingPro Fair Value estimate stands at $6.17 USD, which is in line with UBS's revised price target, suggesting that the stock may be approaching a value territory according to some analysts. Investors are encouraged to stay informed and consider all available data when making investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.